MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF

MET, a receptor protein tyrosine kinase activated by hepatocyte growth factor (HGF), is a crucial determinant of metastatic progression. Recently, we have identified p53 as an important regulator of MET-dependent cell motility and invasion. This regulation occurs via feedforward loop suppressing MET expression by miR-34-dependent and -independent mechanisms. Here, by using Dicer conditional knockout, we provide further evidence for microRNA-independent MET regulation by p53. Furthermore, we show that while MET levels increase immediately after p53 inactivation, mutant cells do not contain active phosphorylated MET and remain non-invasive for a long latency period at contrary to cell culture observations. Evaluation of mouse models of ovarian and prostate carcinogenesis indicates that formation of desmoplastic stroma, associated production of HGF by stromal cells and coinciding MET phosphorylation precede cancer invasion. Thus, initiation mutation of p53 is sufficient for preprogramming motile and invasive properties of epithelial cells, but the stromal reaction may represent a critical step for their manifestation during cancer progression.

[1]  S. Thorgeirsson,et al.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression , 2011, Proceedings of the National Academy of Sciences.

[2]  R. Basha,et al.  Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. , 2011, Gynecologic oncology.

[3]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[4]  W. Walsh,et al.  microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). , 2011, International journal of oncology.

[5]  A. Sood,et al.  Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. , 2011, Neoplasia.

[6]  W. Yeo,et al.  Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. , 2011, International journal of oncology.

[7]  M. Abdelrahim,et al.  Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice , 2011, Investigational New Drugs.

[8]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[9]  D. Roy,et al.  Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. , 2010, The American journal of pathology.

[10]  W. Zipfel,et al.  Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. , 2010, Translational oncology.

[11]  J. Abastado,et al.  Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. , 2010, The Journal of clinical investigation.

[12]  H. Hermeking,et al.  Frequent Downregulation of miR-34 Family in Human Ovarian Cancers , 2010, Clinical Cancer Research.

[13]  M. Abdelrahim,et al.  Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. , 2009, Carcinogenesis.

[14]  Ran Kafri,et al.  Genetic Redundancy: New Tricks for Old Genes , 2009, Cell.

[15]  P. Comoglio,et al.  MicroRNAs impair MET-mediated invasive growth. , 2008, Cancer research.

[16]  A. Neugut,et al.  Mutations in p53, p53 protein overexpression and breast cancer survival , 2008, Journal of Cellular and Molecular Medicine.

[17]  R. Weinberg Leaving home early: reexamination of the canonical models of tumor progression. , 2008, Cancer cell.

[18]  Harold Varmus,et al.  Seeding and Propagation of Untransformed Mouse Mammary Cells in the Lung , 2008, Science.

[19]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[20]  R. Place,et al.  MicroRNA-373 induces expression of genes with complementary promoter sequences , 2008, Proceedings of the National Academy of Sciences.

[21]  W. Zipfel,et al.  Toxicity and Biomedical Imaging of Layered Nanohybrids in the Mouse , 2007, Toxicologic pathology.

[22]  Wei Wang,et al.  MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. , 2007, Cancer research.

[23]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[24]  V. Tarasov,et al.  Differential Regulation of microRNAs by p53 Revealed by Massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest , 2007, Cell cycle.

[25]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[26]  A. Flesken-Nikitin,et al.  Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. , 2007, Cancer research.

[27]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[28]  A. van Oudenaarden,et al.  MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. , 2007, Molecular cell.

[29]  Moshe Oren,et al.  Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. , 2007, Molecular cell.

[30]  E. Kistner,et al.  c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. , 2007, Cancer research.

[31]  R. Place,et al.  Small dsRNAs induce transcriptional activation in human cells , 2006, Proceedings of the National Academy of Sciences.

[32]  David C. Corney,et al.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.

[33]  P. Kuhn,et al.  Immunolocalization of the hepatocyte growth factor (HGF) system in the rat ovary and the anti-apoptotic effect of HGF in rat ovarian granulosa cells in vitro. , 2006, Reproduction.

[34]  M. Abdelrahim,et al.  Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. , 2006, Journal of the National Cancer Institute.

[35]  Noam Shomron,et al.  Canalization of development by microRNAs , 2006, Nature Genetics.

[36]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  F. Dietrich,et al.  Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs , 2006, Nature Genetics.

[38]  R. Russell,et al.  Animal MicroRNAs Confer Robustness to Gene Expression and Have a Significant Impact on 3′UTR Evolution , 2005, Cell.

[39]  A. Vaheri,et al.  Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. , 2005, Cancer research.

[40]  R. Eils,et al.  Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. , 2005, Cancer cell.

[41]  Z. Werb,et al.  Coevolution of cancer and stromal cellular responses. , 2005, Cancer cell.

[42]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[43]  P. Comoglio,et al.  Cancer therapy: can the challenge be MET? , 2005, Trends in molecular medicine.

[44]  J. Boyd,et al.  Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. , 2004, Gynecologic oncology.

[45]  R. Haba,et al.  The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients , 2004, British Journal of Cancer.

[46]  A. Nikitin,et al.  Pathology of Ovarian Neoplasms in Genetically Modified Mice. , 2004, Comparative medicine.

[47]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[48]  S. Mangan,et al.  Structure and function of the feed-forward loop network motif , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Brian J. Smith,et al.  The impact of p53 protein core domain structural alteration on ovarian cancer survival. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  C. Marth,et al.  Why did p53 gene therapy fail in ovarian cancer? , 2003, The Lancet. Oncology.

[51]  A. Flesken-Nikitin,et al.  Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. , 2003, Cancer research.

[52]  D. Rimm,et al.  Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors , 2003, Cancer.

[53]  A. Berns,et al.  Conditional mouse models of sporadic cancer , 2002, Nature Reviews Cancer.

[54]  L. Trusolino,et al.  Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.

[55]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[56]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[57]  P. Leung,et al.  Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? , 2001, Oncogene.

[58]  A. Sood,et al.  The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma , 2000, Cancer.

[59]  A. Berns,et al.  Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. , 2000, Genes & development.

[60]  M. Skinner,et al.  Expression and Action of Hepatocyte Growth Factor in Human and Bovine Normal Ovarian Surface Epithelium and Ovarian Cancer1 , 2000, Biology of reproduction.

[61]  J. Hayashi,et al.  p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. , 1999, Cancer research.

[62]  R. Ness,et al.  Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.

[63]  A. Sood,et al.  Distant metastases in ovarian cancer: association with p53 mutations. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  W. Lee,et al.  Early loss of the retinoblastoma gene is associated with impaired growth inhibitory innervation during melanotroph carcinogenesis in Rb+/- mice. , 1996, Genes & development.

[65]  R. Bast,et al.  The p53 tumor suppressor gene frequently is altered in gynecologic cancers , 1994, American journal of obstetrics and gynecology.

[66]  L. Espey Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. , 1994, Biology of reproduction.

[67]  L. Orci,et al.  Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor , 1991, Cell.

[68]  L. Naldini,et al.  Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. , 1991, The Journal of biological chemistry.

[69]  A. Bardelli,et al.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. , 1991, The EMBO journal.

[70]  W. Birchmeier,et al.  Evidence for the identity of human scatter factor and human hepatocyte growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[71]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[72]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[73]  David C. Corney,et al.  Role of p53 and Rb in ovarian cancer. , 2008, Advances in experimental medicine and biology.

[74]  S. Lai,et al.  Spectrum of p53 Tumor Suppressor Gene Mutations and Breast Cancer Survival , 2004, Breast Cancer Research and Treatment.

[75]  K. Kinzler,et al.  Cancer-susceptibility genes. Gatekeepers and caretakers. , 1997, Nature.

[76]  P. Fialkow,et al.  Clonal origin of human tumors. , 1979, Annual review of medicine.